All In Biotech

Drug Trial Radar · NCT00000859

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,300

Actual

Start

Not stated

Primary completion

Not stated

Study completion Dec 2001

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare nelfinavir (NFV) with ritonavir (RTV) for delaying disease progression or death in HIV-infected patients with CD4+ cell counts less than 100 cells/mm3 \[AS PER AMENDMENT 3/11/98: less than or equal to 200 cells/mm3\]. To compare NFV with RTV for the development of adverse events and for rates of permanent discontinuation of study medication. \[AS PER AMENDMENT 10/02/97: To compare by intention-to-treat analysis for disease progression, including death, the following two regimens: NFV plus background combination antiretroviral (AR) therapy followed by indinavir (IDV) or RTV in the event of significant intolerance; and RTV plus AR therapy followed by IDV, then NFV, in the event of significant intolerance.\] \[AS PER AMENDMENT 3/11/98: SUBSTUDY CPCRA 045: To determine the relative rates of emergence of HIV-1 resistance and to compare changes in plasma HIV RNA levels and CD4+ cell counts in a sample of patients with CD4+ cell counts \<= 200/mm3 who are enrolled in protocol CPCRA 042.\] AR therapy is rapidly becoming the standard of care for the treatment of HIV infection. AR therapy provides the best opportunity for maximizing viral suppression, reducing toxicity and delaying the emergence of resistant strains. The newest class of AR agents, the HIV protease inhibitors, exhibits the most potent anti-HIV effects described to date. This study will compare 2 protease inhibitors, NFV and RTV for efficacy and safety in a population with advanced HIV disease, who are taking various background nucleoside therapies.

Conditions

  • HIV Infections

Interventions

  • Indinavir sulfateDrug

  • RitonavirDrug

  • Nelfinavir mesylateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

44 sites in 2 countries. Site status is shown where the registry gives one.

  • Community Consortium / UCSF

    San Francisco, California

  • Community Consortium of San Francisco

    San Francisco, California

  • Denver Community Program for Clinical Research on AIDS

    Denver, Colorado

  • Denver CPCRA / Denver Pub Hlth / Rocky Mt Cancer Ctr Aurora

    Denver, Colorado

  • Denver CPCRA / Denver Public Hlth

    Denver, Colorado

  • Infectious Disease Physicians / Northern Virginia

    Washington D.C., District of Columbia

  • Timothy A Price

    Washington D.C., District of Columbia

  • Veterans Administration Med Ctr / Regional AIDS Program

    Washington D.C., District of Columbia

  • Washington Reg AIDS Prog / Dept of Infect Dis

    Washington D.C., District of Columbia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • AIDS Research Alliance - Chicago

    Chicago, Illinois

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

    New Orleans, Louisiana

  • Louisiana Community AIDS Research Program

    New Orleans, Louisiana

  • Baltimore TRIALS

    Baltimore, Maryland

  • Westat / NICHD

    Rockville, Maryland

  • Comprehensive AIDS Alliance of Detroit

    Detroit, Michigan

  • Wayne State Univ / Univ Hlth Ctr

    Detroit, Michigan

  • Henry Ford Hosp

    Detroit, Michigan

  • Mercer Area Early Intervention Services

    Camden, New Jersey

  • Southern New Jersey AIDS Clinical Trials

    Camden, New Jersey

  • Southern New Jersey AIDS Cln Trials / Dept of Med

    Camden, New Jersey

  • New Jersey Community Research Initiative

    Newark, New Jersey

  • North Jersey Community Research Initiative

    Newark, New Jersey

  • Partners in Research - New Mexico

    Albuquerque, New Mexico

  • Partners Research

    Albuquerque, New Mexico

  • Harlem AIDS Treatment Group / Harlem Hosp Ctr

    New York, New York

  • Harlem AIDS Treatment Group

    New York, New York

  • Portland Veterans Adm Med Ctr / Rsch & Education Grp

    Portland, Oregon

  • The Research and Education Group

    Portland, Oregon

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • Saint Joseph's Hosp

    Philadelphia, Pennsylvania

  • Richmond AIDS Consortium

    Richmond, Virginia

  • Saint Paul's Hosp

    Vancouver, British Columbia, Canada

  • QEII Health Science Centre

    Halifax, Nova Scotia, Canada

  • Saint Joseph's Hosp

    London, Ontario, Canada

  • Ottawa Gen Hosp

    Ottawa, Ontario, Canada

  • Sunnybrook Health Science Centre

    Toronto, Ontario, Canada

  • Toronto Gen Hosp

    Toronto, Ontario, Canada

  • Wellesley Hosp

    Toronto, Ontario, Canada

  • Hotel - Dieu de Montreal

    Montreal, Quebec, Canada

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.